Roche以53亿美元购买丹麦生物技术的肥胖药物,进入竞争性市场。 Roche buys Danish biotech's obesity drug for $5.3 billion, entering a competitive market.

瑞士一家制药公司Roche已同意与丹麦生物技术新西兰制药公司达成一项53亿美元的交易,开发一种称为石丁酸的肥胖药物并将其商业化。 Roche, a Swiss pharmaceutical company, has agreed to a $5.3 billion deal with Danish biotech Zealand Pharma to develop and commercialize an obesity drug called petrelintide. 新西兰制药公司收到一笔16.5亿美元的预付付款,有可能收到额外的里程碑付款。 Zealand Pharma receives an upfront payment of $1.65 billion, with potential for additional milestone payments. 协议的目的是扩大到日益扩大的肥胖药物市场,影响诺沃·诺迪斯克和伊莱·莉莉等竞争者。 The deal aims to expand into the growing obesity drug market, impacting competitors like Novo Nordisk and Eli Lilly.